Lowe Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Lowe Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4	Closed	-$225	–	316
2023 Q2	$225	Hold	4	–	–	﹤0.01%	346
2023 Q1	$181	Hold	4	–	–	﹤0.01%	341
2022 Q4	$163	Hold	4	–	–	﹤0.01%	349
2022 Q3	$0	Hold	4	–	–	﹤0.01%	338
2022 Q2	$0	Hold	4	–	–	﹤0.01%	317
2022 Q1	$0	Hold	4	–	–	﹤0.01%	319
2021 Q4	$0	Hold	4	–	–	﹤0.01%	297
2021 Q3	$0	Hold	4	–	–	﹤0.01%	282
2021 Q2	$1K	Hold	4	–	–	﹤0.01%	260
2021 Q1	$0	Hold	4	–	–	﹤0.01%	275
2020 Q4	$1K	Hold	4	–	–	﹤0.01%	247
2020 Q3	$0	Hold	4	–	–	﹤0.01%	260
2020 Q2	$0	Hold	4	–	–	﹤0.01%	271
2020 Q1	$0	Buy	+4	New	+$207	﹤0.01%	312

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lowe Wealth Advisors's CRSP Position: Q3 2023 in Review

Lowe Wealth Advisors sold out of CRISPR Therapeutics (CRSP) in Q3 2023, closing a stake of 4 shares — an estimated $225 sold.

Lowe Wealth Advisors first reported a position in CRSP in Q1 2020 and held it in 14 quarters. The position peaked at $1K in Q2 2021. 406 funds tracked by Wall St. Rank hold CRSP as of Q3 2023.

Lowe Wealth Advisors reported no remaining CRISPR Therapeutics position as of Q3 2023 after selling out during the quarter.
Lowe Wealth Advisors sold 4 CRISPR Therapeutics shares in Q3 2023, an estimated $225.
Lowe Wealth Advisors first reported a position in CRISPR Therapeutics in Q1 2020 and held it in 14 quarters.
Lowe Wealth Advisors's CRISPR Therapeutics position peaked at $1K in Q2 2021.
406 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2023.

Based on Lowe Wealth Advisors's 13F filing for Q3 2023, filed 23 Oct 2023.